Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)

BACKGROUND: Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab + pertuzumab plus chemotherapy regimens for pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuanjia, Xiang, Hongyu, Xin, Ling, Duan, Xuening, Liu, Yinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771321/
https://www.ncbi.nlm.nih.gov/pubmed/36535009
http://dx.doi.org/10.1097/CM9.0000000000002197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771321/
https://www.ncbi.nlm.nih.gov/pubmed/36535009
http://dx.doi.org/10.1097/CM9.0000000000002197

Ejemplares similares